

TABLE OF CONTENTS

PREFACE.....	xvii
ACKNOWLEDGEMENTS.....	xxi
LIST OF CONTRIBUTORS	xxv
LIST OF FIGURES	xxxi
LIST OF TABLES.....	xxxiii
LIST OF BOXES.....	xxxvii

INTRODUCTION: CONCEPTS IN THE RELATIONSHIP OF CONGENITAL DISEASES WITH THE ENVIRONMENT

P. NICOLOPOULOU-STAMATI

Summary.....	1
1. Introduction.....	2
2. The changing concepts of environmental influences in the causation of congenital anomalies	3
3. Methods to study congenital anomalies and their links to the environment.....	4
3.1. EUROCAT: Surveillance of environmental impact	4
3.2. Endpoints for prenatal exposures in toxicological studies.....	4
3.3. Evidence from wildlife.....	5
3.4. Epidemiology	6
3.5. Clinical teratology.....	6
4. Chemicals and exposure conditions associated with congenital anomalies	7
4.1. Congenital diseases related to environmental exposure to dioxins	7
4.2. Association of intra-uterine exposure with drugs: the thalidomide effect.....	7
4.3. Endocrine disrupter exposure and male congenital malformations.....	8
4.4. Links between in utero exposure to pesticides and their effects on human progeny. Does European pesticide policy protect health?	9
4.5. Phthalates	9
5. Environmental congenital anomalies	10
5.1. Testicular dysgenesis syndrome	10
5.2. Endocrine disrupters, inflammation and steroidogenesis	10

5.3. Environmental impact on congenital diseases: the case of cryptorchidism	11
6. Policy aspects.....	12
6.1. Raising awareness of information society on impact of EU policies and deployment aspects	12
6.2. The concerns of NGO's related to congenital diseases	12
6.3. Environmental impacts on congenital anomalies – information for the non-expert professional.....	13
7. Conclusions.....	13
References	14

SECTION 1: METHODS

ENDPOINTS FOR PRENATAL EXPOSURES IN TOXICOLOGICAL STUDIES

A. MANTOVANI AND F. MARANGHI

Summary	21
1. Introduction.....	22
2. An overview of regulatory tests in developmental toxicology.....	24
2.1. Prenatal development toxicity study (OECD guideline 414)	24
2.2. Two-generation reproduction toxicity study (OECD 416).....	26
2.3. <i>In vitro</i> alternative tests for developmental toxicity.....	28
2.4. Developmental toxicity testing of environmental contaminants. The example of endocrine disrupters.	30
3. Recommendations for further research in developmental toxicology.....	31
Acknowledgements	32
References	32

CONGENITAL DEFECTS OR ADVERSE DEVELOPMENTAL EFFECTS IN VERTEBRATE WILDLIFE: THE WILDLIFE-HUMAN CONNECTION

G. LYONS

Summary	37
1. Introduction: The animal – human connection and epigenetic reprogramming	38
2. Summary of pollutant-related defects reported in wildlife	41
2.1. Fish.....	43
2.1.1. Deformities of sex-linked structures in fish	46
2.1.2. Poor reproductive success / reduced hatching in fish.....	47
2.1.3. Thyroid disruption in fish.....	47

2.1.4. Immunosuppression in fish.....	48
2.1.5. Altered osmoregulation in migrating fish.....	48
2.2. Birds.....	48
2.2.1. Abnormal VTG production in male birds.....	49
2.2.2. Deformities of the reproductive tract, and ovo-testes in birds.....	49
2.2.3. Embryonic mortality and reduced reproductive success in birds.....	49
2.2.4. Altered thyroid function in birds.	50
2.2.5. Immunosuppression in birds.....	50
2.2.6. Eggshell thinning in birds.....	51
2.2.7. Deformities of the bill and bone in birds.....	51
2.3. Reptiles.....	52
2.3.1. Effects in alligators.....	52
2.3.2. Effects on turtles.....	53
2.4. Amphibians.....	54
2.5. Mammals.....	56
2.5.1. Feral rodents.....	56
2.5.2. Otters.....	56
2.5.3. Mink.....	58
2.5.4. Seals and sea lions: Reproductive problems, immunosuppression, adrenal and other effects in seals.....	59
2.5.5. Whales and other cetaceans.....	60
2.5.6. Polar bears.....	62
2.5.7. Black and brown bears.....	64
2.5.8. Florida panther.....	65
2.5.9. Sitka black tail deer.....	65
2.5.10. White tailed deer.....	66
2.5.11. Mule deer.....	66
2.5.12. Eland.....	66
3. Summary of some effects found in both humans and wildlife.....	67
3.1. Testicular dysgenesis syndrome / Intersex.....	67
3.2. Thyroid disruption.....	68
3.3. Immunotoxicity.....	69
3.4. Congenital defects of jaw, beak, claw, nails or teeth.....	71
4. Conclusions.....	71
References.....	72

EPIDEMIOLOGICAL METHODS

A. ROSANO AND E. ROBERT-GNANSIA

Summary.....	89
1. Introduction.....	89
2. Sources of data, coding and classification.....	92

2.1. Source of data for congenital anomalies	92
2.2. Coding and classification of congenital anomalies	93
2.3. Accuracy of diagnosis and ascertainment of congenital anomalies	94
2.4. Source of data, coding and assessment of environmental exposures	95
3. Study designs	97
3.1. Cohort or follow-up study	99
3.2. Case-control studies	101
3.3. Ecological designs	103
3.3.1. Exploratory studies.....	105
3.3.2. Multiple-group comparison study	107
3.3.3. Space-time cluster study.....	107
3.4. Case reports.....	109
4. Genetic epidemiology	109
4.1. Study designs in genetic epidemiology.....	110
5. Problems in environmental epidemiology when studying its effects on reproduction	113
5.1. Living status of cases	113
5.2. Genetic susceptibility.....	115
5.3. Rare diseases, low-level exposures, and small effects	115
5.4. Identifying, quantifying, and timing exposures.....	116
5.5. Sources of errors	117
6. Conclusions.....	121
References.....	123

EUROCAT: SURVEILLANCE OF ENVIRONMENTAL IMPACT

H. DOLK

Summary	131
1. EUROCAT: What and why?.....	132
2. The prevalence of congenital anomalies	134
3. Environmental causes of congenital anomalies	135
4. EUROCAT surveillance of environmental impact	137
4.1. Approaches to surveillance	137
4.1.1. Assessment of trends in congenital anomaly prevalence.....	138
4.1.2. Routine detection of and response to clusters without a well defined a priori exposure hypothesis.....	138
4.1.3. Systematic evaluation of environmental exposures.....	139
4.2. Envirovigilance	141
References	142

CLINICAL TERATOLOGY

M. CLEMENTI AND E. DI GIANANTONIO

Summary.....	147
1. Introduction.....	148
2. Teratogens.....	149
2.1. Basic principles of clinical teratology.....	150
2.2. Animal studies.....	151
2.3. Pharmacokinetics in pregnancy.....	152
2.4. Methods to identify human teratogens.....	153
2.5. Classification of drugs used in pregnancy.....	154
2.6. Criteria for proof of human teratogenicity.....	155
2.7. Teratogen Information Services (TIS) in Europe.....	155
3. Conclusions.....	157
References.....	159

SECTION 2: TERATOGENS**DIOXINS AND CONGENITAL MALFORMATIONS**

J.G. KOPPE, M. LEIJS, G. TEN TUSSCHER AND P.D. BOER

Summary.....	163
1. Introduction.....	164
2. Acute dioxin poisoning.....	166
2.1. Animal studies.....	166
2.2. Acute dioxin toxicity in man.....	166
2.2.1. Yushchenko.....	166
2.2.2. Two secretaries.....	167
2.3. Hormones.....	167
2.4. Thrombocytopenia.....	168
3. Hotspots of dioxin pollution.....	169
3.1. Amsterdam Diemerzeedijk 1961-1973.....	169
3.2. Yusho-disaster 1968.....	170
3.3. Yucheng-disaster 1978.....	170
3.4. Seveso-disaster 1976.....	171
3.5. Vietnam: Agent Orange spraying 1962-1971.....	172
3.6. Bashkortostan: 1965-1985.....	173
3.7. Chapaevsk 1967-1987.....	174
3.7.1. Prematurity.....	174
3.7.2. Intra-uterine growth retardation.....	174
3.7.3. Congenital morphogenetic conditions.....	174
3.7.4. Congenital malformations.....	175
3.7.5. Congenital hydrocephaly without spina bifida.....	175

3.7.6. Increasing type 1 diabetes	177
4. The role of vitamin A.....	177
5. Conclusion	178
References	178

LINKS BETWEEN *IN UTERO* EXPOSURE TO PESTICIDES AND EFFECTS ON THE HUMAN PROGENY. DOES EUROPEAN PESTICIDE POLICY PROTECT HEALTH?

C. WATTIEZ

Summary	183
1. Introduction.....	184
2. Congenital disorders	185
2.1. Congenital malformations.....	186
2.1.1. Several birth defects.....	186
2.1.2. Central nervous system defects	187
2.1.3. Cardiovascular defects	187
2.1.4. Orofacial clefts	188
2.1.5. Urogenital defects	188
2.1.6. Limb defects.....	188
2.2. Other congenital disorders	192
2.2.1. Intrauterine growth retardation.....	193
2.2.2. Neurodevelopmental impairments.....	193
3. Does European pesticide policy protect our health?	196
3.1. The plant protection product authorisation directive	196
3.1.1. Regulatory testing shortcomings.....	196
3.1.2. No consideration for combined effects.....	197
3.1.3. Toxic properties of the formulated products are not properly evaluated	198
3.1.4. No systematic review of the scientific literature is required	198
3.1.5. No exclusion criteria are defined for active substances, based on intrinsic properties.....	198
3.1.6. Exposure evaluation deficits	199
3.1.7. The substitution principle and comparative assessment are not considered	199
3.2. The thematic strategy on the sustainable use of pesticides	200
4. Conclusions.....	201
References	203

ASSOCIATION OF *INTRA-UTERINE* EXPOSURE TO DRUGS WITH CONGENITAL DEFECTS: THE THALIDOMIDE EFFECT

M. CLEMENTI, K. LUGWIG AND A. ANDRISANI

Summary.....	207
1. Introduction.....	208
2. Pharmacokinetics	209
3. Mechanism of action	210
4. Thalidomide side-effects	212
5. “New” indications.....	213
5.1. Leprosy.....	215
5.2. Human Immunodeficiency Virus (HIV)	215
5.3. Beucet disease	215
5.4. Dermatological and autoimmune disorders.....	215
5.5. Cancer complications	216
6. STEPS programme (System for thalidomide education and prescribing safety).....	216
7. Lessons for environmental teratology	217
8. Conclusions.....	218
References	218

SECTION 3: CONGENITAL DISEASES

ENDOCRINE DISRUPTER EXPOSURE AND MALE CONGENITAL MALFORMATIONS

M.F. FERNÁNDEZ AND N. OLEA

Summary.....	225
1. Introduction.....	226
2. Review of the epidemiological evidence.....	227
3. The case of Southern Spain	232
4. Difficulties in exposure assessment: Implications for future research	235
Acknowledgements	237
References	241

TESTICULAR DYSGENESIS SYNDROME AS A CONGENITAL DISEASE

H.E. VIRTANEN AND J. TOPPARI

Summary.....	245
1. Introduction.....	246

2. Semen quality and testicular cancer.....	246
3. Birth rates of cryptorchidism and hypospadias.....	247
4. Discussion.....	248
Acknowledgements.....	249
References.....	249

ENDOCRINE DISRUPTERS, STEROIDOGENESIS AND INFLAMMATION

K. SVECHNIKOV, V. SUPORNSILCHAI, I. SVECHNIKOVA,
M. STRAND, C. ZETTERSTRÖM, A. WAHLGREN, O. SÖDER

Summary.....	255
1. Introduction.....	256
2. The role of androgens in male fetal differentiation.....	256
3. Functions of the fetal Leydig cell.....	258
4. Impact of endocrine disrupters on male reproductive health.....	259
5. Effects of environmental anti-androgens on the reproductive development and hormonal functions of Leydig cells.....	260
5.1. Procymidone.....	260
5.2. Linuron.....	261
5.3. Vinclozolin.....	262
5.4. p,p' DDT and its derivatives.....	263
6. Effects of phthalates on Leydig cell function and reproductive development.....	264
7. Effects of dioxin on androgen production by Leydig cells and on reproductive health.....	265
8. Effects of endocrine disrupters on adrenal function.....	266
9. Effects of endocrine disrupters on the hormonal functions of ovarian cells....	268
10. Endocrine disrupters, inflammation and androgen production.....	271
11. Conclusions.....	273
Acknowledgements.....	274
References.....	274

ENVIRONMENTAL IMPACT ON CONGENITAL DISEASES: THE CASE OF CRYPTORCHIDISM. WHERE ARE WE NOW, AND WHERE ARE WE GOING?

P.F. THONNEAU, E. HUYGHE AND R. MIEUSSET

Summary.....	281
1. Background.....	282
2. Has the incidence of cryptorchidism increased?.....	283
3. Increasing evidence of a link between various male reproductive health issues....	285

4. Toxic effect of anti-androgenic compounds on male reproductive health	286
4.1. The evidence-based central role of Sertoli cells and androgen production in testis and male reproductive tract development	286
4.2. A potential role of Insulin-like growth factor (InsI3).....	287
4.3. A non-exhaustive list of environmental chemicals with anti-androgenic effects	288
5. Limited data on environmental impact of cryptorchidism in humans	289
5.1. DES	289
5.2. Epidemiological studies (occupational and environmental conditions) ..	289
5.3. Bioaccumulation of chemical compounds.....	289
6. Where do we go from here, and how can we answer the question?	290
References	291

ENVIRONMENTAL RISK AND SEX RATIO IN NEWBORNS

M. PETERKA, Z. LIKOVSKY AND R. PETERKOVA

Summary.....	295
1. Introduction	296
2. Basic manifestations of developmental damage.....	297
2.1. Lethality - prenatal loss	297
2.2. Major malformations	299
2.2.1. Prenatal extinction of major malformations	300
2.3. Minor malformations usually manifest as functional defects	301
2.4. Intrauterine growth retardation and low birth weight.....	301
3. Dose response in teratology	302
3.1. Substances with teratogenic and lethal effects	303
3.2. Substances with a predominantly lethal effect	304
3.3. Substances with neither a teratogenic nor a lethal effect.....	304
4. Residual teratogenesis and the epidemiology of malformations	304
5. Sex ratio	306
5.1. Sex determination.....	306
5.2. Newborn sex ratio	307
5.3. Newborn sex ratio and the vulnerability of male embryos/fetuses.....	307
6. Chernobyl.....	309
6.1. Radioactive clouds and whole body radioactivity	309
6.2. Newborn sex ratio – November 1986.....	310
6.3. Critical period for radiation.....	311
6.4. Hypothesis about the reasons for the selective abortion of male fetuses after the Chernobyl disaster.....	312
7. Conclusion.....	313
References	313

SECTION 4: COUNTRY REPORTS

CONGENITAL ABNORMALITIES IN GREECE: FUNCTIONAL EVALUATION OF STATISTICAL DATA 1981 – 1995

E. BRILAKIS, E. FOUSTERIS AND J. PAPADOPULOS

Summary	323
1. Introduction.....	324
2. Method.....	325
3. Results.....	326
4. Discussion.....	334
4.1. Specific mortality and infant mortality ratios.....	334
4.2. Variations of the ratios within Greece.....	335
4.3. Hospitalisation due to birth defects within Greece	336
4.4. Deaths/hospitalisation ratio due to births defects in Greece	336
5. Conclusions.....	337
References.....	337

CONGENITAL ANOMALIES IN BULGARIA

E. TERLEMESIAN AND S. STOYANOV

Summary	339
1. Introduction.....	340
2. Congenital diseases in Bulgaria: The Sofia register database.....	341
3. Mortality rates.....	345
4. Discussion.....	350
5. Conclusions.....	354
References.....	355

CONGENITAL ANOMALIES IN THE BRITISH ISLES

J. RANKIN

Summary	359
1. Introduction.....	360
1.1. Recording of congenital anomalies in the British Isles.....	360
1.1.1. The national congenital anomaly system.....	361
1.1.2. Regional congenital anomaly registers.....	362
1.1.3. Disease-specific registers	366
1.1.4. The British Isles network of congenital anomaly registers.....	367
2. Variations in the prevalence of congenital anomalies in the British Isles.....	368
2.1. Secular trends in congenital anomaly prevalence	368
2.2. Regional variations in congenital anomaly prevalence	369

3. Use of data from congenital anomaly registers in environment and health research in the British Isles	371
3.1. Cluster investigations	372
3.1.1. Geographical variation in congenital anomaly rates	372
4. Conclusion.....	373
Acknowledgements	374
References	374

EUROPEAN UNION-FUNDED RESEARCH ON ENDOCRINE DISRUPTERS AND UNDERLYING POLICY

T. KARJALAINEN

Summary.....	379
1. Introduction.....	380
1.1. Path to adoption of community strategy for endocrine disrupters.....	380
1.2. Community strategy for endocrine disrupters	381
1.2.1. Short-term strategy	381
1.2.2. Medium-term strategy	382
1.2.3. Long-term strategy	383
2. European Commission-sponsored research on endocrine disrupters	384
2.1. Research activities in the fourth research framework programme (1994-1998).....	384
2.2. Research activities in the fifth framework programme of research (FP5: 1998-2002)	384
2.2.1. Key-action 4: environment and health.....	385
2.2.2. Projects funded by the Energy, Environment and Sustainable Development (EESD) thematic programme	396
2.3. Research activities in the sixth framework programme of research (FP6: 2002-2006)	396
2.3.1. Outcome of first, second, and third calls for proposals	396
3. Research activities in the seventh framework programme of research (FP7: 2006-2013).....	402
4. Conclusion.....	404
References	404

SECTION 5: CONCLUSIONS

ENVIRONMENTAL IMPACTS ON CONGENITAL ANOMALIES - INFORMATION FOR THE NON-EXPERT PROFESSIONAL

L. HENS

Summary.....	409
--------------	-----

1. Introduction.....	410
2. Problem identification.....	412
3. Methodological approaches	414
3.1. Clinical evidence.....	414
3.2. Epidemiological evidence	417
3.3. Evidence from experimental developmental toxicology	424
3.4. Evidence from wildlife studies.....	426
4. Mechanisms causing congenital anomalies.....	429
5. Implications for stakeholders	433
5.1. Advising in the public health sector	434
5.2. Lawyers and legal advisers	435
5.3. Policy makers and advisors.....	435
5.4. Scientists and media.....	437
6. Discussion and conclusions	439
References	443
 LIST OF ABBREVIATIONS	 451
 LIST OF UNITS.....	 455
 INDEX	 457